Chemours Company (The) Company Profile (NYSE:CC)

About Chemours Company (The) (NYSE:CC)

Chemours Company (The) logoThe Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a North American provider of industrial chemicals used in gold production, oil and gas, water treatment and other industries. It delivers customized solutions with a range of industrial and specialty chemical products for markets, including plastics and coatings, refrigeration and air conditioning, industrial, mining and oil refining. Its products include titanium dioxide, refrigerants, industrial fluoropolymer resins and a portfolio of mining and industrial chemicals, including sodium cyanide. As of December 31, 2016, the Company operates 26 production facilities located in 10 countries.

Industry, Sector and Symbol:
  • Sector: Basic Materials
  • Industry: Commodity Chemicals
  • Sub-Industry: N/A
  • Symbol: NYSE:CC
  • CUSIP: N/A
  • Web: www.chemours.com
Capitalization:
  • Market Cap: $10.35625 billion
  • Outstanding Shares: 184,800,000
Average Prices:
  • 50 Day Moving Avg: $51.25
  • 200 Day Moving Avg: $44.05
  • 52 Week Range: $14.73 - $57.08
P/E:
  • Trailing P/E Ratio: 38.01
  • Foreward P/E Ratio: 11.40
  • P/E Growth: 10.55
Sales & Book Value:
  • Annual Revenue: $5.74 billion
  • Price / Sales: 1.84
  • Book Value: $3.07 per share
  • Price / Book: 18.57
Dividend:
  • Annual Dividend: $0.12
  • Dividend Yield: 0.2%
Profitability:
  • EBITDA: $1.07 billion
  • Net Margins: 4.96%
  • Return on Equity: 122.97%
  • Return on Assets: 6.77%
Debt:
  • Debt-to-Equity Ratio: 7.09%
  • Current Ratio: 1.97%
  • Quick Ratio: 1.48%
Misc:
  • Average Volume: 2.02 million shs.
  • Beta: 3.6
  • Short Ratio: 0.85
 

Frequently Asked Questions for Chemours Company (The) (NYSE:CC)

What is Chemours Company (The)'s stock symbol?

Chemours Company (The) trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

How often does Chemours Company (The) pay dividends? What is the dividend yield for Chemours Company (The)?

Chemours Company (The) announced a quarterly dividend on Wednesday, August 2nd. Investors of record on Thursday, August 17th will be paid a dividend of $0.03 per share on Friday, September 15th. This represents a $0.12 annualized dividend and a yield of 0.21%. The ex-dividend date of this dividend is Tuesday, August 15th. View Chemours Company (The)'s Dividend History.

How were Chemours Company (The)'s earnings last quarter?

Chemours Company (The) (NYSE:CC) issued its earnings results on Wednesday, August, 2nd. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.85 by $0.02. The firm earned $1.59 billion during the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The firm's quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the business posted $0.27 EPS. View Chemours Company (The)'s Earnings History.

When will Chemours Company (The) make its next earnings announcement?

Chemours Company (The) is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Chemours Company (The).

Where is Chemours Company (The)'s stock going? Where will Chemours Company (The)'s stock price be in 2017?

6 analysts have issued twelve-month target prices for Chemours Company (The)'s stock. Their predictions range from $27.00 to $60.00. On average, they anticipate Chemours Company (The)'s share price to reach $51.83 in the next twelve months. View Analyst Ratings for Chemours Company (The).

What are analysts saying about Chemours Company (The) stock?

Here are some recent quotes from research analysts about Chemours Company (The) stock:

  • 1. According to Zacks Investment Research, "Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company's brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington. " (10/3/2017)
  • 2. Jefferies Group LLC analysts commented, "Clarity on the PFOA liability significantly reduces Chemours' risk profile, and the stock has responded accordingly. In our view, the next 18 months are a story of delivering on cost controls, leveraging and extending Opteon, and managing TiO2 as the industry shifts from a restock cycle to a potential improvement in underlying demand." (2/15/2017)

Who are some of Chemours Company (The)'s key competitors?

Who are Chemours Company (The)'s key executives?

Chemours Company (The)'s management team includes the folowing people:

  • Richard H. Brown, Independent Chairman of the Board
  • Mark P. Vergnano, President, Chief Executive Officer, Director
  • Mark E. Newman, Chief Financial Officer, Senior Vice President
  • Paul Kirsch, President - Fluoroproducts
  • Christian W. Siemer, President - Chemical Solutions
  • E. Bryan Snell, President - Titanium Technologies
  • Elizabeth Albright, Senior Vice President - Human Resources
  • Erich Parker, Vice President of Corporate Communications, Chief Brand Officer
  • David Charles Shelton, Corporate Secretary and General Counsel
  • Curtis V. Anastasio, Independent Director

Who owns Chemours Company (The) stock?

Chemours Company (The)'s stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Park National Corp OH (0.00%). Company insiders that own Chemours Company (The) stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Paul Kirsch, Richard H Brown, Stephen D Newlin and Thierry Fj Vanlancker. View Institutional Ownership Trends for Chemours Company (The).

Who bought Chemours Company (The) stock? Who is buying Chemours Company (The) stock?

Chemours Company (The)'s stock was acquired by a variety of institutional investors in the last quarter, including Park National Corp OH. Company insiders that have bought Chemours Company (The) stock in the last two years include Bradley J Bell, Mark Newman, Richard H Brown, Stephen D Newlin and Thierry Fj Vanlancker. View Insider Buying and Selling for Chemours Company (The).

How do I buy Chemours Company (The) stock?

Shares of Chemours Company (The) can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chemours Company (The)'s stock price today?

One share of Chemours Company (The) stock can currently be purchased for approximately $57.01.


MarketBeat Community Rating for Chemours Company (The) (NYSE CC)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  304
MarketBeat's community ratings are surveys of what our community members think about Chemours Company (The) and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Chemours Company (The) (NYSE:CC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $51.83 (9.08% downside)
Consensus Price Target History for Chemours Company (The) (NYSE:CC)
Price Target History for Chemours Company (The) (NYSE:CC)
Analysts' Ratings History for Chemours Company (The) (NYSE:CC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017ArgusReiterated RatingBuy$50.00 -> $55.00HighView Rating Details
8/4/2017J P Morgan Chase & CoBoost Price TargetOverweight$55.00LowView Rating Details
8/4/2017Citigroup Inc.Boost Price TargetBuy$45.00 -> $59.00HighView Rating Details
8/3/2017Jefferies Group LLCBoost Price TargetBuy$60.00HighView Rating Details
5/15/2017Susquehanna Bancshares IncBoost Price TargetPositive$45.00 -> $55.00LowView Rating Details
2/13/2017Goldman Sachs Group, Inc. (The)UpgradeNeutral -> BuyN/AView Rating Details
5/9/2016Barclays PLCBoost Price TargetOverweight$14.00 -> $15.00N/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for Chemours Company (The) (NYSE:CC)
Earnings by Quarter for Chemours Company (The) (NYSE:CC)
Earnings History by Quarter for Chemours Company (The) (NYSE CC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017$0.95N/AView Earnings Details
8/2/2017Q2 2017$0.85$0.87$1.49 billion$1.59 billionViewListenView Earnings Details
5/1/2017Q1 2017$0.50$0.75$1.32 billion$1.44 billionViewListenView Earnings Details
2/15/2017Q416$0.29$0.08$1.24 billion$1.30 billionViewN/AView Earnings Details
11/6/2016Q3 2016$0.25$0.61$1.29 billion$1.40 billionViewN/AView Earnings Details
8/8/2016Q216$0.17$0.27$1.42 billion$1.38 billionViewN/AView Earnings Details
5/2/2016Q116$0.02$0.06$1.27 billion$1.30 billionViewN/AView Earnings Details
2/23/2016Q415$0.09$0.03$1.36 billion$1.40 billionViewListenView Earnings Details
11/5/2015Q315$0.26$0.40$1.52 billion$1.49 billionViewN/AView Earnings Details
8/6/2015Q215$0.33$0.24$1.53 billion$1.50 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Chemours Company (The) (NYSE:CC)
2017 EPS Consensus Estimate: $3.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.51$0.51$0.51
Q2 20171$0.94$0.94$0.94
Q3 20171$0.97$0.97$0.97
Q4 20171$0.96$0.96$0.96
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Chemours Company (The) (NYSE:CC)
Most Recent Dividend:9/15/2017
Annual Dividend:$0.12
Dividend Yield:0.21%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:8.11% (Trailing 12 Months of Earnings)
3.31% (Based on This Year's Estimates)
2.40% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Chemours Company (The) (NYSE:CC)

Dividend History by Quarter for Chemours Company (The) (NYSE CC)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/2/2017quarterly$0.030.25%8/15/20178/17/20179/15/2017
4/27/2017quarterly$0.030.3%5/15/20175/17/20176/15/2017
2/14/2017quarterly$0.030.37%2/23/20172/27/20173/15/2017
11/2/2016quarterly$0.030.72%11/15/201611/17/201612/15/2016
8/3/2016quarterly$0.031.34%8/15/20168/17/20169/15/2016
4/27/2016quarterly$0.031.27%5/13/20165/17/20166/15/2016
2/23/2016quarterly$0.032.44%3/9/20163/11/20163/31/2016
9/1/2015quarterly$0.031.38%11/10/201511/13/201512/14/2015
7/24/2015special$0.557/30/20158/3/20159/11/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Chemours Company (The) (NYSE:CC)
Insider Ownership Percentage: 1.14%
Institutional Ownership Percentage: 72.91%
Insider Trades by Quarter for Chemours Company (The) (NYSE:CC)
Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)
Insider Trades by Quarter for Chemours Company (The) (NYSE:CC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2017David C SheltonSVPSell5,908$56.01$330,907.08View SEC Filing  
10/10/2017David C SheltonSVPSell13,397$55.00$736,835.00View SEC Filing  
10/5/2017David C SheltonSVPSell19,000$53.68$1,019,920.00View SEC Filing  
9/5/2017E Bryan SnellInsiderSell13,000$49.35$641,550.00View SEC Filing  
8/31/2017David C. SheltonSVPSell13,337$48.48$646,577.76View SEC Filing  
8/11/2017Amy TrojanowskiVPSell2,500$46.03$115,075.00View SEC Filing  
8/11/2017E Bryan SnellInsiderSell10,000$46.24$462,400.00View SEC Filing  
6/5/2017Paul KirschInsiderSell19,036$41.42$788,471.12View SEC Filing  
5/16/2017Erich ParkerVPSell4,908$45.53$223,461.24View SEC Filing  
5/5/2017Mark NewmanVPSell22,781$39.83$907,367.23View SEC Filing  
5/3/2017Richard H. BrownDirectorBuy2,500$39.10$97,750.00View SEC Filing  
5/13/2016Mark NewmanCFOBuy2,800$9.71$27,188.00View SEC Filing  
5/4/2016Bradley J BellDirectorBuy10,000$9.65$96,500.00View SEC Filing  
2/26/2016Stephen D. NewlinDirectorBuy10,000$4.94$49,400.00View SEC Filing  
11/23/2015Thierry Fj VanlanckerInsiderBuy15,000$6.00$90,000.00View SEC Filing  
9/14/2015E Bryan SnellInsiderBuy8,000$8.89$71,120.00View SEC Filing  
9/11/2015Amy TrojanowskiVPBuy5,400$9.24$49,896.00View SEC Filing  
9/10/2015Christian W SiemerInsiderBuy10,100$9.39$94,839.00View SEC Filing  
9/9/2015Mark NewmanCFOBuy10,600$9.32$98,792.00View SEC Filing  
9/8/2015Christian W SiemerInsiderBuy11,000$9.11$100,210.00View SEC Filing  
9/4/2015David C SheltonSVPBuy5,000$9.00$45,000.00View SEC Filing  
9/4/2015Mark P VergnanoCEOBuy72,600$9.25$671,550.00View SEC Filing  
9/4/2015Stephen D. NewlinDirectorBuy7,000$9.18$64,260.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Chemours Company (The) (NYSE:CC)
Latest Headlines for Chemours Company (The) (NYSE:CC)
Source:
DateHeadline
americanbankingnews.com logoChemours Company (The) (CC) SVP Sells $330,907.08 in Stock
www.americanbankingnews.com - October 13 at 10:30 PM
msn.com logoKronos Worldwide (KRO) Up 24% in 3 Months: What's Driving It?
www.msn.com - October 13 at 5:38 PM
americanbankingnews.com logoChemours Company (The) (CC) SVP David C. Shelton Sells 13,397 Shares
www.americanbankingnews.com - October 12 at 10:20 PM
nasdaq.com logoCC Crosses Above Average Analyst Target
www.nasdaq.com - October 12 at 5:48 PM
finance.yahoo.com logoEx-Chemours employee accused by U.S. of trade secrets theft scheme
finance.yahoo.com - October 12 at 5:48 PM
finance.yahoo.com logoChemours Company, (The) -- Moody's upgrades Chemours to Ba2; outlook stable.
finance.yahoo.com - October 12 at 5:48 PM
americanbankingnews.com logoChemours Company (The) (CC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 2:50 PM
nasdaq.com logoChemours (CC) Up 34% in 3 Months: What's Driving the Stock? - Nasdaq
www.nasdaq.com - October 10 at 6:13 PM
finance.yahoo.com logoChemours (CC) Up 34% in 3 Months: What's Driving the Stock?
finance.yahoo.com - October 9 at 5:43 PM
finance.yahoo.com logoChemours (CC) Up 34% in 3 Months: What's Driving the Stock?
finance.yahoo.com - October 9 at 5:43 PM
americanbankingnews.com logoChemours Company (The) (CC) SVP Sells $1,019,920.00 in Stock
www.americanbankingnews.com - October 5 at 10:28 PM
finance.yahoo.com logoChemours Announces Dates for Third Quarter 2017 Earnings Release and Webcast Conference Call
finance.yahoo.com - October 5 at 9:03 PM
prnewswire.com logoOpteon™ 1100 Wins 2017 Polyurethane Innovation Award - PR Newswire (press release)
www.prnewswire.com - October 5 at 4:02 PM
finance.yahoo.com logoOpteon™ 1100 Wins 2017 Polyurethane Innovation Award
finance.yahoo.com - October 5 at 11:45 AM
bizjournals.com logoHow These Specialty Chemicals Stocks are Performing? -- Green Plains, Olin, PPG Industries, and Chemours
www.bizjournals.com - October 4 at 12:29 PM
finance.yahoo.com logoChemours' (CC) Solid Product Offerings Make it a Must Buy
finance.yahoo.com - October 3 at 4:52 PM
finance.yahoo.com logoETFs with exposure to The Chemours Co. : October 3, 2017
finance.yahoo.com - October 3 at 4:52 PM
finance.yahoo.com logoThe Chemours Co. :CC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 2, 2017
finance.yahoo.com - October 2 at 3:30 PM
americanbankingnews.com logoTraders Buy High Volume of Chemours Company (The) Call Options (CC)
www.americanbankingnews.com - October 2 at 9:44 AM
americanbankingnews.com logoHead-To-Head Comparison: Chemours Company (The) (CC) & Ingevity Corp (NGVT)
www.americanbankingnews.com - September 30 at 6:26 AM
americanbankingnews.com logoChemours Company (The) (CC) and Westlake Chemical Partners (WLKP) Critical Comparison
www.americanbankingnews.com - September 29 at 10:10 PM
prnewswire.com logoChemours Files Appeal Concerning SNAP 20 Rule to Regulate HFCs - PR Newswire (press release)
www.prnewswire.com - September 23 at 2:04 AM
finance.yahoo.com logoChemours Files Appeal Concerning SNAP 20 Rule to Regulate HFCs
finance.yahoo.com - September 22 at 9:01 PM
nasdaq.com logoChemours (CC) Hits New 52-Week High: What's Driving It? - Nasdaq
www.nasdaq.com - September 21 at 3:36 PM
finance.yahoo.com logoTronox Will Raise $450 Million through Senior Notes
finance.yahoo.com - September 18 at 3:28 PM
americanbankingnews.com logoChemours Company (The) (CC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 17 at 12:54 PM
finance.yahoo.com logoChemours Has Continued Its Upward Momentum in 2017
finance.yahoo.com - September 14 at 5:41 PM
finance.yahoo.com logoChemours: Analyzing Its 3Q17 Dividend
finance.yahoo.com - September 13 at 6:12 PM
finance.yahoo.com logoWhy Is Chemours’ Dividend Yield Low?
finance.yahoo.com - September 13 at 6:12 PM
finance.yahoo.com logoChemours: Analysts’ Recommendations and More
finance.yahoo.com - September 13 at 6:12 PM
americanbankingnews.com logoInsider Selling: Chemours Company (The) (CC) Insider Sells 13,000 Shares of Stock
www.americanbankingnews.com - September 7 at 10:24 PM
americanbankingnews.com logoContrasting Braskem (BAK) & Chemours Company (The) (CC)
www.americanbankingnews.com - September 7 at 6:16 AM
msn.com logoHere's Why Koninklijke DSM (RDSMY) Is a Good Investment Pick
www.msn.com - September 6 at 4:59 PM
finance.yahoo.com logoPPG Industries Closes Remaining Fiberglass Operations Sale
finance.yahoo.com - September 6 at 4:59 PM
finance.yahoo.com logoTop Ranked Growth Stocks to Buy for September 6th
finance.yahoo.com - September 6 at 4:59 PM
seekingalpha.com logoNorth Carolina threatens legal action against Chemours
seekingalpha.com - September 5 at 6:33 PM
msn.com logoFMC Corp Poised on Lithium Unit Strength, Growth Actions
www.msn.com - September 5 at 8:03 AM
americanbankingnews.com logoChemours Company (The) (CC) SVP Sells $646,577.76 in Stock
www.americanbankingnews.com - September 5 at 7:18 AM
msn.com logoEastman Chemical's New Projects to Boost CHDM Capacity
www.msn.com - September 4 at 5:03 PM
americanbankingnews.com logoHead-To-Head Comparison: Quaker Chemical Corporation (KWR) versus Chemours Company (The) (CC)
www.americanbankingnews.com - September 1 at 2:14 PM
nasdaq.com logo6 Reasons That Make Chemours (CC) a Solid Choice Right Now - Nasdaq
www.nasdaq.com - August 30 at 3:20 PM
finance.yahoo.com logoTop Ranked Growth Stocks to Buy for August 30th
finance.yahoo.com - August 30 at 3:20 PM
finance.yahoo.com logoInnophos Declares Closure of Novel Ingredients Acquisition
finance.yahoo.com - August 29 at 10:25 PM
nasdaq.com logoWhy Chemours Company (CC) Could Be an Impressive Growth ... - Nasdaq
www.nasdaq.com - August 25 at 11:44 PM
finance.yahoo.com logoWhy Chemours Company (CC) Could Be an Impressive Growth Stock
finance.yahoo.com - August 25 at 6:43 PM
americanbankingnews.com logoReviewing Chemours Company (The) (CC) and UFP Technologies (UFPT)
www.americanbankingnews.com - August 25 at 1:02 PM
nasdaq.com logo5 Solid Relative Price Strength Stocks for Assured Returns - Nasdaq
www.nasdaq.com - August 24 at 10:13 PM
zacks.com logoHere's Why You Should Buy Chemours Company (CC) Stock Now
www.zacks.com - August 21 at 4:54 PM
americanbankingnews.com logoFY2020 EPS Estimates for Chemours Company (The) Lifted by Jefferies Group (CC)
www.americanbankingnews.com - August 21 at 10:02 AM
americanbankingnews.com logoChemours Company (The) (CC) Insider E Bryan Snell Sells 10,000 Shares
www.americanbankingnews.com - August 15 at 10:22 PM

Social

Chart

Chemours Company (The) (CC) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.